Investors in Actinium Pharmaceuticals Urged to Join Class Action Lawsuit Amid Allegations of Misleading Statements

Actinium Pharmaceuticals Shareholder Class Action Alert

On April 24, 2025, The Gross Law Firm issued an important notice urging shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) who have incurred losses to step forward regarding a pending class action lawsuit. The alert highlights significant allegations against the company, particularly concerning misleading statements made during a critical trial period.

Overview of the Allegations

The allegations center on the company’s data from the Phase 3 Sierra trial, which reportedly failed to comply with the FDA's criteria for acceptance regarding the BLA (Biologics License Application) for its targeted radiotherapy, Iomab-B. Specifically, the claims state that:

1. During the class period, the company issued false or misleading statements about its trial results, leading investors to believe the FDA would accept the BLA.
2. Data from the trial was likely insufficient to meet the FDA’s stringent guidelines, and the optimistic projections provided by the company were unfounded.
3. Due to the inadequacy of the trial data, the FDA might either refuse to review or reject the BLA application if considered.
4. The misleading communication caused investors to have a distorted view of Actinium's operational success and future potential, resulting in financial losses.

Class Action Participation

Shareholders who acquired shares of ATNM during the class action period from October 31, 2022, to August 2, 2024, are encouraged to register for participation. To take part in the lawsuit, interested shareholders must register by May 27, 2025, indicating their purchases during the defined timeframe. It's critical to act promptly to ensure eligibility.

Signing up for the class action provides access to ongoing updates throughout the resolution process with no immediate financial obligation. Registering as a shareholder allows individuals to monitor their potential claims against Actinium Pharmaceuticals continuously.

Next Steps for Investors

If you are one of the shareholders affected by the aforementioned events, or if you have invested in the company during the specified period, now is the time to take action. You can register easily online at The Gross Law Firm’s designated portal for this class action. Investors should not hesitate, as timing is crucial, and the deadline for lead plaintiff applications is approaching.

For those who may have questions regarding the legal procedure or need further clarity about the allegations, The Gross Law Firm offers professional support. Recognized nationally for their thorough approach to class action laws and investors' rights, they are committed to advocating for those who believe they have been misled by corporate communications.

Why Choose The Gross Law Firm?

With a strong track record of success, The Gross Law Firm stands out due to its commitment to safeguarding the interests of investors. Their research-intensive approach ensures that companies uphold ethical standards in their communication and operations. Investors can feel reassured that their case is being pursued by experienced professionals dedicated to achieving recovery for those wronged by deceptive business practices.

For personalized queries, shareholders can contact:

- The Gross Law Firm

15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Stay informed and proactive as you navigate this opportunity to reclaim potential losses resulting from what may potentially be corporate misconduct.